C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cutia Therapeutics
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Other Current Liabilities
ÂĄ45.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Liabilities
ÂĄ1.5B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Liabilities
ÂĄ1.8B
CAGR 3-Years
38%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Liabilities
ÂĄ1.9B
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Liabilities
ÂĄ2.5B
CAGR 3-Years
23%
CAGR 5-Years
55%
CAGR 10-Years
58%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Liabilities
ÂĄ121.8m
CAGR 3-Years
33%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Other Current Liabilities?
Other Current Liabilities
45.1m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Other Current Liabilities amounts to 45.1m CNY.

What is Cutia Therapeutics's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 1Y
45%

Over the last year, the Other Current Liabilities growth was 45%.

Back to Top